Document Detail


Treatment of adenovirus infections in the immunocompromised host.
MedLine Citation:
PMID:  15248091     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Adenovirus infections are increasing as causes of morbidity and mortality in severely immunocompromised patients. The currently available antiviral agents, ribavirin and cidofovir, have yielded mixed results in case reports and small case series. Similar to cytomegalovirus disease, established adenovirus disease is often difficult to treat. Therapy may yield poor results, even when effective antiviral drugs are used. New strategies, including pre-emptive therapy, should be tested in prospective, clinical trials. New agents and adoptive transfer of specific T-cells to adenovirus might improve the current situation.
Authors:
P Ljungman
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2004-07-10
Journal Detail:
Title:  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology     Volume:  23     ISSN:  0934-9723     ISO Abbreviation:  Eur. J. Clin. Microbiol. Infect. Dis.     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-08-23     Completed Date:  2004-10-28     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  8804297     Medline TA:  Eur J Clin Microbiol Infect Dis     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  583-8     Citation Subset:  IM    
Affiliation:
Department of Haematology, Karolinska University Hospital/Huddinge, 14186 Stockholm, Sweden. per.ljungman@medhs.ki.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae Infections / drug therapy*,  epidemiology*,  immunology
Antiviral Agents / therapeutic use*
Clinical Trials as Topic
Cytosine / analogs & derivatives*,  therapeutic use
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Ganciclovir / therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Immunocompromised Host*
Male
Organ Transplantation
Organophosphonates*
Organophosphorus Compounds / therapeutic use
Prognosis
Ribavirin / therapeutic use
Severity of Illness Index
Transplantation Immunology
Treatment Outcome
Vidarabine / therapeutic use
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Organophosphonates; 0/Organophosphorus Compounds; 36791-04-5/Ribavirin; 5536-17-4/Vidarabine; 71-30-7/Cytosine; 82410-32-0/Ganciclovir; JIL713Q00N/cidofovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ram horn peptone as a source of citric acid production by Aspergillus niger, with a process.
Next Document:  A new confirmatory Neisseria gonorrhoeae real-time PCR assay targeting the porA pseudogene.